Clinical relivance of immunoscore in gastric cancer

Clinical relivance of immunoscore in gastric cancer - Clinical relivance of immunoscore in gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046593

Enrollment

1000

Registered

2022-01-09

Start date

2021-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as gastric cancer which are proven by biopsy as adenocarinoma and can receive radical resection.

Exclusion criteria

Exclusion criteria: Synchronous or metachronous (within 5 years) malignancies

Design outcomes

Primary

Measure	Time frame
Percentage expression of tumor infiltrating immune cells (CD3, CD8, CD45RO, etc.)	—

Secondary

Measure	Time frame
1, Relationship between the expression rate of tumor-infiltrating immune cells (CD3, CD8, CD45RO, etc.) and prognosis and chemotherapy response 2, Expression rate of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) 3, Association between the expression rate of tumor-infiltrating immune cells (CD3, CD8, CD45RO, etc.) and the expression rate of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) 4, Association between expression rates of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) and prognosis and chemotherapy response Translated with www.DeepL.com/Translator (free version)	—

Measure

Time frame

1, Relationship between the expression rate of tumor-infiltrating immune cells (CD3, CD8, CD45RO, etc.) and prognosis and chemotherapy response 2, Expression rate of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) 3, Association between the expression rate of tumor-infiltrating immune cells (CD3, CD8, CD45RO, etc.) and the expression rate of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) 4, Association between expression rates of immune checkpoint molecules (PD-L1, PD-L2, PD-1, TIM-3, CTLA-4, ICOS, LAG3, etc.) and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) and prognosis and chemotherapy response Translated with www.DeepL.com/Translator (free version)

—

Countries

Japan

Contacts

Public ContactTakuro Saito

Osaka University Clinical Research Group for Gastroenterological Study Osaka University Clinical Research Group for Gastroenterological Study

tsaito@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results